Stock·NASDAQ·Healthcare
IDEXX Laboratories, Inc. (IDXX)
- Market cap
- $43.16B
- P/E
- 37.60
- Dividend yield
- 0.00%
- Street target
- $705.00median of 13 analysts
- 52-week range
- $500.61 $769.98
The short version
Where IDXX stands today, in four lines, and what CleaRank Financial AI makes of it.
IDXX at a glance
IDEXX Laboratories, Inc. (IDXX): Sell, 21/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 50-day but below its 200-day moving average ($535.84 and $580.28).
- Earnings IDXX beat estimates in 8 of its last 8 quarters, yet fell the next day after 5 of those beats.
- Insiders Insiders sold $75.1M and made no open-market purchases over the last 18 months.
- Valuation P/E of 37.6 against 31.9 for the Healthcare sector: broadly in line with peers (+18%).
Figures as of October 16, 2026.
CleaRank Financial AI
IDEXX Laboratories, Inc. (IDXX) is currently trading at $547.18, below its 200-day simple moving average of $580.28, signaling a bearish trend.
Despite this technical weakness, Wall Street maintains a 'Buy' consensus with a median price target of $705.00, implying an upside of 28.8%. The company operates in the Diagnostics & Research industry within Healthcare, a sector with a median P/E of 31.90 and revenue growth of 8.10%. IDXX's own profit margin stands at 25.03%, and its return on equity is a strong 74.21%, indicating strong profitability. However, substantial insider selling, totaling $75.1 million against zero purchases, presents a significant risk. This heavy selling pressure from officers, despite a 'Buy' rating from 13 analysts, warrants caution.
Only on CleaRank
Figures we compute ourselves from IDXX's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
1/4Price above its 50-day average ›
The price of $547.18 is 2.1% above the 50-day simple moving average of $535.84.Price above its 200-day average ›
The price is 5.7% below the 200-day simple moving average of $580.28.50-day average above the 200-day ›
The 50-day average ($535.84) is 7.7% below the 200-day average ($580.28), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 17% of its 52-week range, between $500.61 and $769.98.
IDXX share price
Pick a period: each tab shows how far IDXX has moved over it, to the last close.
Today's trading
Where IDXX sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
2/4P/E below the sector median ›
The trailing P/E of 37.60 is 17.9% above the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 9.16 is 169.6% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $1.1B on revenue of $4.6B, a net margin of 25.0%.Beat estimates in most recent reports ›
IDXX beat the EPS estimate in 8 of its last 8 reports.
Key statistics
The headline figures for IDXX.
As of October 16, 2026, IDXX trades at $547.18, with a market value of $43.16B and a P/E ratio of 37.60.
What the numbers say
CleaRank Financial AI's reading of IDXX's valuation, growth and risks.
IDEXX Laboratories (IDXX) trades at a P/E ratio of 37.60, which is higher than the Healthcare sector median of 31.90, suggesting a premium valuation.
Its price-to-sales ratio is 9.16, also above the sector median of 3.40. However, the company boasts a strong profit margin of 25.03% and an exceptional return on equity of 74.21%, significantly outperforming the sector's median ROE of 7.30%. The debt-to-equity ratio is 0.68, aligning with the sector average. While fundamentals are strong, the current valuation appears stretched relative to sector averages, especially given the significant insider selling.
IDXX against the Healthcare sector
How IDXX compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (18% difference), suggesting fair market pricing relative to industry standards.
Return vs XLV: Since May 5, 2025, IDXX has gained 15.2% against a gain of 28.9% for XLV.
Performance against XLV
IDXX and the Healthcare sector fund over the same days.
Revenue and earnings
How much IDXX sells, and how much of it becomes profit.
Revenue growth: Revenue grew 10.4% in FY2025 to $4.3B, from $3.9B a year earlier.
Profit margin: The net margin was 24.6% in FY2025, up from 22.8% the year before.
Profitable: IDXX earned $1.1B in FY2025.
Earnings reality check
Did IDXX beat what analysts expected, and how did the stock react?
Earnings record: IDXX beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 5 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 4, 2026after close | $3.93 | $4.27 | +8.65% | -0.56% | -0.25% |
| May 5, 2026after close | $3.41 | $3.47 | +1.76% | +2.89% | -5.16% |
| Feb 2, 2026after close | $2.94 | $3.08 | +4.76% | -1.10% | +0.03% |
| Nov 3, 2025after close | $3.15 | $3.40 | +7.94% | -0.11% | -1.85% |
| Aug 4, 2025after close | $3.30 | $3.63 | +10.00% | -5.98% | -4.49% |
| May 1, 2025after close | $2.84 | $2.96 | +4.23% | +0.11% | +3.95% |
| Feb 3, 2025after close | $2.40 | $2.62 | +9.17% | -0.85% | -0.88% |
| Oct 31, 2024after close | $2.69 | $2.80 | +4.09% | +2.55% | +6.41% |
As of October 16, 2026, IDXX has beaten the analyst EPS estimate in 8 of its last 8 reported quarters and fell in the first trading session after 5 of those beats; its latest report, on August 4, 2026, came in 8.65% above the estimate and the stock moved -0.56% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 61.3, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 61.3 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of IDXX
The score, the reasoning behind it, and what could move the price next.
IDEXX Laboratories (IDXX) is trading below its 200-day simple moving average of $580.28, indicating a bearish trend.
The stock is currently above its 50-day SMA of $535.84 and its 20-day EMA of $523.99, suggesting some short-term support. The 14-day RSI is at 61.34, signaling bullish momentum, while the MACD is slightly negative at -0.41. Key support levels are near the 50-day SMA, while resistance lies at the 200-day SMA and potentially higher targets. Volume on the latest trading day was slightly below its average, offering no strong conviction for either direction.
Consistent EPS Beat Performance ›
IDXX has a history of exceeding analyst EPS estimates, most recently with an 8.65% surprise in its August 2026 earnings report, demonstrating operational strength.
Source: Earnings ReportsStrong Profitability and ROE ›
The company maintains a high profit margin of 25.03% and an exceptional return on equity of 74.21%, significantly outperforming sector averages.
Source: Company Fundamentals
Heavy Insider Selling Pressure ›
Insiders have sold over $75.1 million worth of IDXX stock with no reported purchases.
Source: Insider FilingsPrice Below 200-Day Moving Average ›
IDXX is trading below its 200-day SMA of $580.28, a key technical indicator suggesting a bearish trend and potential for further downside movement.
Source: Technical Analysis
- The stock is trading below its 200-day moving average, suggesting a bearish trend. Consider waiting for a confirmed break above this level before initiating new long positions.
- Given the P/E ratio of 37.60, which is above the sector median, investors should ensure that IDEXX Laboratories' growth prospects justify the premium valuation.
Technical indicators
Momentum and trend for IDXX, from its daily closes.
As of October 16, 2026, with IDXX at $547.18, its 14-day RSI is 61.3 (showing bullish momentum without being overbought), its 50-day simple moving average is $535.84 and its 200-day is $580.28.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What IDXX moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, IDXX's 1-year correlation of daily returns is +0.43 with S&P 500 (SPY), +0.35 with Nasdaq 100 (QQQ), +0.12 with Bitcoin (BTC) and +0.09 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
8 of 13 analysts rate it a buy or strong buy, 4 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $705.00 is 28.8% above the price.More buy ratings than three months ago ›
8 of 13 rate it a buy now, against 9 of 15 three months ago.
IDXX Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 11, 2026 | Barclays | Maintains | Overweight |
| Aug 5, 2026 | UBS | Maintains | Neutral |
| Aug 5, 2026 | Citigroup | Maintains | Neutral |
| Jul 27, 2026 | UBS | Maintains | Neutral |
| Apr 28, 2026 | UBS | Maintains | Neutral |
As of October 16, 2026, 13 Wall Street analysts cover IDXX: 8 rate it a buy or strong buy, 4 a hold and 1 a sell or strong sell. Their 12-month price targets range from $470.00 to $805.00, with a median of $705.00, 28.8% above the price of $547.18.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
IDXX trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Short entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from IDXX's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much IDXX tends to move, against the market and on its own.
The long record
IDXX's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
4/4Average daily move under 2% ›
The price has moved 1.46% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 52.7%, from August 2021 to October 2022, regained by November 2025.Most 1-year holds ended higher ›
77% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $49,176, against $42,525 in the S&P 500 (SPY).
IDXX Drawdowns & Recovery
As of October 16, 2026, IDXX's worst peak-to-trough fall over the last 10 years with dividends reinvested was -52.7% (August 2021 to October 2022); it regained that peak by November 2025, 37 months after the low, and 77% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into IDXX in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: IDXX beat the S&P 500 over this period: $49,176 against $42,525.
A $10,000 investment in IDXX in October 2016 would be worth about $49,176 today with dividends reinvested, compared with about $42,525 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to IDXX, and which have not.
Strongest month, July: an average of +6.83%, up in 8 of 10 years.
Weakest month, September: an average of -2.85%, up in 3 of 10 years.
This month, October: has averaged -0.47%, up in 5 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, IDXX's strongest calendar month has been July (average +6.83%, up in 8 of 10 years) and its weakest September (average -2.85%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in IDXX, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in IDXX today could grow to about $25,338 by 2036 in the base case, with a 90th-percentile outcome near $95,323 and a 10th-percentile outcome around $6,735. Projections are statistical simulations, not guarantees.
IDXX Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $794 for IDXX by 2030 in the base case, from $547 today (1.5x over 4 years). The 10th-percentile path ends near $343. These are outcomes of a Monte Carlo simulation run on IDXX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $395 | $600 | $913 | |
| 2028 | $364 | $659 | $1,192 | |
| 2029 | $350 | $723 | $1,494 | |
| 2030 | $343 | $794 | $1,835 | |
| 2031 | $341 | $871 | $2,223 |
Method: a lognormal simulation of IDXX's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
IDXX insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought IDXX shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 16, 2026, IDXX insiders reported 18 open-market sales worth $75.1M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 4, 2026 | Lawrence D Kingsley
Director
|
Sell | 2.2K | $1.2M |
| Sep 4, 2026 | Lawrence D Kingsley
Director
|
Option | 2.2K | $251.5K |
| Aug 20, 2026 | Andrew Emerson
Chief Financial Officer
|
Option | 265 | $47.2K |
| Jul 30, 2026 | Joseph L. Hooley
Director
|
Grant | 49 | $27.4K |
| Jun 1, 2026 | George Fennell
Officer
|
Grant | 639 | - |
| May 7, 2026 | Joseph L. Hooley
Director
|
Grant | 158 | - |
| May 7, 2026 | Daniel M Junius
Director
|
Grant | 257 | - |
| May 7, 2026 | Lawrence D Kingsley
Director
|
Grant | 339 | - |
| May 7, 2026 | Karen Peacock
Director
|
Grant | 101 | - |
| May 7, 2026 | Margaret Anne Szostak
Director
|
Grant | 257 | - |
| May 7, 2026 | Sophie V Vandebroek
Director
|
Grant | 257 | - |
| Apr 30, 2026 | Joseph L. Hooley
Director
|
Grant | 43 | $24.1K |
| Mar 3, 2026 | Nimrata K Hunt
Officer
|
Sell | 1.8K | $1.1M |
| Mar 3, 2026 | Sharon E Underberg
General Counsel
|
Option | 197 | $99.6K |
| Feb 27, 2026 | Jonathan Jay Mazelsky
Chief Executive Officer
|
Option | 23.5K | $3.4M |
| Feb 26, 2026 | Jonathan Jay Mazelsky
Chief Executive Officer
|
Sell | 23.3K | $15.3M |
| Feb 26, 2026 | Nimrata K Hunt
Officer
|
Sell | 2.7K | $1.8M |
| Feb 19, 2026 | Michael G Erickson
Officer
|
Option | 7.8K | $1.5M |
| Feb 17, 2026 | Michael G Erickson
Officer
|
Sell | 5.4K | $3.4M |
| Feb 17, 2026 | Sophie V Vandebroek
Director
|
Sell | 1.5K | $920.3K |
| Feb 17, 2026 | Sophie V Vandebroek
Director
|
Option | 945 | $315.5K |
| Feb 13, 2026 | Andrew Emerson
Chief Financial Officer
|
Grant | 456 | - |
| Feb 13, 2026 | Michael G Erickson
Officer
|
Grant | 2.4K | - |
| Feb 13, 2026 | George Fennell
Officer
|
Grant | 454 | - |
| Feb 13, 2026 | Nimrata K Hunt
Officer
|
Grant | 2.6K | - |
| Feb 13, 2026 | Michael Perkins Johnson
Officer
|
Grant | 573 | - |
| Feb 13, 2026 | Michael J Lane
Officer
|
Grant | 1.1K | - |
| Feb 13, 2026 | Jonathan Jay Mazelsky
Chief Executive Officer
|
Grant | 2.1K | - |
| Feb 13, 2026 | Michael Schreck
Officer
|
Grant | 2.0K | - |
| Feb 13, 2026 | Martin Alexander Smith
Officer
|
Grant | 1.0K | - |
| Feb 13, 2026 | Sharon E Underberg
General Counsel
|
Grant | 832 | - |
| Feb 10, 2026 | George Fennell
Officer
|
Sell | 11.3K | $7.3M |
| Feb 10, 2026 | George Fennell
Officer
|
Option | 12.8K | $869.9K |
| Jan 30, 2026 | Joseph L. Hooley
Director
|
Grant | 36 | $24.1K |
| Nov 7, 2025 | Nimrata K Hunt
Officer
|
Sell | 9.4K | $6.6M |
| Nov 7, 2025 | Nimrata K Hunt
Officer
|
Option | 12.5K | $4.8M |
| Oct 30, 2025 | Joseph L. Hooley
Director
|
Grant | 39 | $24.5K |
| Aug 29, 2025 | Martin Alexander Smith
Officer
|
Grant | 18 | - |
| Aug 22, 2025 | Margaret Anne Szostak
Director
|
Sell | 2.2K | $1.4M |
| Aug 22, 2025 | Margaret Anne Szostak
Director
|
Grant | 259 | - |
| Aug 22, 2025 | Margaret Anne Szostak
Director
|
Option | 2.2K | $451.9K |
| Aug 15, 2025 | Jonathan Jay Mazelsky
Chief Executive Officer
|
Grant | 1.1K | - |
| Aug 12, 2025 | Michael G Erickson
Officer
|
Sell | 405 | $263.8K |
| Aug 12, 2025 | Nimrata K Hunt
Officer
|
Option | 1.2K | $299.3K |
| Aug 12, 2025 | Sharon E Underberg
General Counsel
|
Option | 5.6K | $1.2M |
| Aug 11, 2025 | Nimrata K Hunt
Officer
|
Sell | 1.2K | $787.8K |
| Aug 8, 2025 | Sharon E Underberg
General Counsel
|
Sell | 5.5K | $3.6M |
| Aug 8, 2025 | Jonathan Jay Mazelsky
Chief Executive Officer
|
Option | 183 | $109.5K |
| Aug 7, 2025 | Andrew Emerson
Chief Financial Officer
|
Option | 1.8K | $261.8K |
| Aug 6, 2025 | Jonathan Jay Mazelsky
Chief Executive Officer
|
Sell | 29.3K | $18.5M |
| Aug 6, 2025 | Michael J Lane
Officer
|
Sell | 8.4K | $5.3M |
| Aug 6, 2025 | Nimrata K Hunt
Officer
|
Sell | 7.1K | $4.5M |
| Aug 6, 2025 | Nimrata K Hunt
Officer
|
Option | 12.8K | $2.4M |
| Aug 6, 2025 | Michael J Lane
Officer
|
Option | 8.4K | $2.3M |
| Aug 6, 2025 | Jonathan Jay Mazelsky
Chief Executive Officer
|
Option | 29.3K | $2.0M |
| May 30, 2025 | Michael Perkins Johnson
Officer
|
Grant | 3.4K | - |
| May 21, 2025 | Margaret Anne Szostak
Director
|
Sell | 2.3K | $1.2M |
| May 21, 2025 | Margaret Anne Szostak
Director
|
Option | 1.0K | $167.7K |
| May 13, 2025 | Daniel M Junius
Director
|
Sell | 2.7K | $1.4M |
| May 13, 2025 | Daniel M Junius
Director
|
Option | 2.7K | $707.8K |
| May 9, 2025 | Sophie V Vandebroek
Director
|
Sell | 1.3K | $628.4K |
| May 9, 2025 | Sophie V Vandebroek
Director
|
Option | 1.3K | $362.7K |
| May 6, 2025 | Stuart M Essig
Director
|
Grant | 262 | - |
| May 6, 2025 | Daniel M Junius
Director
|
Grant | 262 | - |
| May 6, 2025 | Lawrence D Kingsley
Director
|
Grant | 346 | - |
| May 6, 2025 | Margaret Anne Szostak
Director
|
Grant | 262 | - |
| May 6, 2025 | Sophie V Vandebroek
Director
|
Grant | 262 | - |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 16, 2026.